Filing Flows › Comparisons › GYRE vs MGNX
Gyre Therapeutics vs Macrogenics: GYRE and MGNX compared
Gyre Therapeutics is the larger company: $32.9M of revenue in its latest quarter (Q3 2026) against $32.8M for Macrogenics (Q2 2026). Macrogenics is growing faster (+378% against +0.7% a year earlier). Gyre Therapeutics is more profitable, with an operating margin of -4.6% against -42.2%.
Where the money goes: GYRE and MGNX
Gyre Therapeutics (GYRE) · Q3 2026
Gyre Therapeutics, Q3 2026: revenue $32.9M (+0.7% year over year), operating margin -4.6%, net loss $2.5M, operating cash flow −$4.0M. The chart follows the revenue to costs, profit and cash.
Macrogenics (MGNX) · Q2 2026
Macrogenics, Q2 2026: revenue $32.8M (+378% year over year), operating margin -42.2%, net earnings $19.5M, operating cash flow −$40.7M. The chart follows the revenue to costs, profit and cash.
| Gyre Therapeutics (GYRE) | Macrogenics (MGNX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $32.9M | $32.8M |
| Revenue growth, Y/Y | +0.7% | +378% |
| Operating margin | -4.6% | -42.2% |
| Net earnings | −$2.5M | $19.5M |
| Net margin | -7.5% | 59.4% |
| Operating cash flow | −$4.0M | −$40.7M |
Where the revenue comes from
Gyre Therapeutics
- Gyre Pharmaceuticals: $32.4M (98%)
- Gyre: $508K (2%)
Macrogenics
- Collaborative and other agreements: $25.5M (78%)
- Royalty revenue: $7.3M (22%)
Questions
Which is bigger, Gyre Therapeutics or Macrogenics?
Gyre Therapeutics is the larger company: $32.9M of revenue in its latest quarter (Q3 2026) against $32.8M for Macrogenics (Q2 2026).
Is Gyre Therapeutics or Macrogenics growing faster?
Macrogenics is growing faster (+378% against +0.7% a year earlier).
Which is more profitable, Gyre Therapeutics or Macrogenics?
Gyre Therapeutics is more profitable, with an operating margin of -4.6% against -42.2%.
More: Gyre Therapeutics earnings · how Gyre Therapeutics makes money · Macrogenics earnings · how Macrogenics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Aug 14, 2026). Fiscal quarters can end on different dates. Not investment advice.